A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Launched by BRISTOL-MYERS SQUIBB · Apr 25, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with advanced lung cancer, specifically a type called metastatic or recurrent non-small cell lung cancer (NSCLC). The study is testing two different ways to give a medication called Nivolumab, which is injected under the skin, along with another medication called Ipilimumab that is given through an IV, and chemotherapy. The goal is to see how effective this combination is for patients who have not received any prior treatment for their cancer.

To be eligible for this trial, participants need to have confirmed stage IV or recurrent NSCLC and should not have received any previous systemic treatments for their cancer. They should also have measurable disease, meaning that doctors can see the cancer using imaging tests like CT or MRI. Additionally, participants must be generally healthy enough to participate, with a performance status of 1 or lower, which indicates they can carry out normal activities with only minor limitations. This trial is not yet recruiting participants, but it aims to provide valuable insights into new treatment options for lung cancer patients.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Participants must have histologically confirmed stage IV or recurrent non-small cell lung cancer (NSCLC) (as defined by the 9th edition of the IASLC Lung Cancer Staging Guidelines) of squamous or non-squamous histology.
• • Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therapy for advanced or metastatic disease.
• • Participants with prior definitive chemoradiation for locally advanced disease is permitted as long as the last administration of chemotherapy or radiotherapy (whichever was given last) occurred at least 6 months prior to randomization. Participants with locally advanced disease with recurrence after chemoradiation therapy (stage III disease, specifically refers to patients with no curative options) are eligible to enroll.
• • Participants with prior adjuvant or neoadjuvant chemotherapy for early-stage lung cancer are permitted if completed at least 6 months prior to randomization.
• • Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1 at screening and confirmed prior to randomization.
• • Participants must have measurable disease by CT or MRI per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with radiographic tumor assessment performed within 28 days of randomization.
• • Exclusion Criteria
• • Participants must not have any prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
• • Participants must not have any known driver mutations with available targeted therapy (including but not limited to EGFR mutations, ALK translocations, ROS-1 translocations and known BRAFV600E, that are sensitive to available targeted inhibitor therapy; participants with a known activating RET mutations and NTRK fusion gene alterations).
• • Participants must not have any untreated central nervous system (CNS) metastases
• • Participants must not have leptomeningeal metastases (carcinomatous meningitis).
• • Participants must not have any active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
• • Participants with previous malignancies (except non-melanoma skin cancers, and in situ cancers such as the following: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to randomization and no additional therapy is required or anticipated to be required during the study period.
• • Participants must not have a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid \> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
• • Participants must not have any history of interstitial lung disease or pneumonitis that required oral or IV glucocorticoids to assist with management.
• • Other protocol-defined Inclusion/Exclusion criteria apply.